New therapies and new goals for psoriatic arthritis

Arthritis and Rheumatism

Volumn 63, Issue 4, 2011, Pages 874-876

  Veale, Douglas James ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; RHEUMATOID FACTOR; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADAPTIVE IMMUNITY; ARTHROPATHY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DACTYLITIS; DENDRITIC CELL; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENTHESITIS; HUMAN; INFLAMMATION; INTERPHALANGEAL JOINT; JOINT EROSION; KERATINOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; NAIL DYSTROPHY; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; ONYCHOLYSIS; OSTEITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REMISSION; RHEUMATOID ARTHRITIS; SHORT FORM 36; SPONDYLOARTHROPATHY; STREPTOCOCCUS INFECTION; SYNOVITIS; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT DURATION; UVEITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOCONJUGATES; MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79953708222     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30173     Document Type: Editorial

References (6)

1. Veale D, Rogers S, FitzGerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-8. (Pubitemid 24051604)
2. Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am 2005;31:641-57. (Pubitemid 41608447)
3. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.
4. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, doubleblind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63: 934-48.
5. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii26-9.
6. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7.